X0306 4 2019-02-27 0 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001704234 Doogan Declan C/O BIOHAVEN PHARMACEUTICALS 215 CHURCH STREET NEW HAVEN CT 06510 1 0 0 0 Common Shares 2019-02-27 4 S 0 6875 44.17 D 394083 D Common Shares 2019-02-27 4 S 0 18270 45.25 D 375813 D Common Shares 2019-02-27 4 S 0 1900 45.86 D 373913 D Common Shares 2019-02-27 4 S 0 23384 45.71 D 1076597 I By the Declan Doogan 2014 Trust Common Shares 2019-03-01 4 S 0 595 45.41 D 1076002 I By the Declan Doogan 2014 Trust Common Shares 2019-03-01 4 S 0 50000 47.19 D 1026002 I By the Declan Doogan 2014 Trust These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.74 - $44.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.75 - $45.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.75 - $46.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $46.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.01 - $47.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. /s/ Darren K. DeStefano, Attorney-in-Fact 2019-03-01